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Summary
Objective: To determine whether an intra-articular injection of recombinant human bone morphogenetic protein-2 (rhBMP-2) alleviates cartilage
degradation in a rat model of osteoarthritis (OA) of the lumbar facet joint.
Method: The right-side facet joint OA model was created by an intra-articular injection of collagenase (type II) 2 weeks before treatment. The
OA rats were divided into four groups: (1) no treatment, or intra-articular injection of either (2) saline, (3) rhBMP-2 10 ng, or (4) rhBMP-2
100 ng. The left-side facet joint served as the normal control. At 3 and 6 weeks after treatment, histological analyses were performed on
the cartilage, synovium, subchondral bone and bone marrow. The cartilage and synovium were graded using a modiﬁed Mankin score
and a synovium score system. Extracellular type II collagen was evaluated by immunohistochemistry.
Results: Intra-articular injection of collagenase causes OA-like changes in the facet joint. OA rats treated with rhBMP-2 at both dosages tested
showed reduced severity of their cartilage lesions compared with untreated and saline-treated groups. There was a statistically signiﬁcant
difference in the modiﬁed Mankin score compared to the untreated and saline-treated groups. However, some rhBMP-2-treated rats at the
higher dose (100 ng) showed, as a side effect, joint space obliteration caused by cartilage overgrowth. Also OA rats treated with 100 ng of
rhBMP-2 displayed a signiﬁcant synovium reaction at 3 weeks compared with that in other groups. Immunohistochemical analysis showed
that treatment with rhBMP-2 signiﬁcantly increased the content of type II collagen.
Conclusion: This study demonstrates the potential efﬁcacy of rhBMP-2 in the alleviation of arthritic changes in a rat model of OA of the lumbar
facet joint. However, treatment with a high dosage of rhBMP-2 caused adverse side effects in some animals.
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Cartilage
Repair
SocietyIntroduction
The facet joint (zygapophysial joint) is a synovial joint, cov-
ered by hyaline cartilage and is enclosed by the synovium
and the joint capsule1,2. In degenerative lumbar spinal
disorders, osteoarthritis (OA) of the facet joint is one of
the causes of low back pain3. Facet joints are clinically im-
portant sources of chronic pain even after spinal fusion or
artiﬁcial intervertebral disc implantation4,5. Current treat-
ment methods in facet joint arthritis include range of motion
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Received 31 January 2007; revision accepted 21 April 2007.13exercises, injection of steroid into the joint6,7, or radiofre-
quency denervation8e10. However, none of these methods
focuses directly on the degenerative process of articular
cartilage.
Bone morphogenetic proteins (BMPs) are multi-functional
growth factors that belong to the transforming growth factor
beta superfamily. BMPs play important roles in embryonic
development and skeletal growth11e13. BMP-2 is currently
approved for multiple indications in the area of bone fracture
repair and spinal fusion. The injection of the recombinant
human BMP-2 (rhBMP-2) alone into muscle tissue is sufﬁ-
cient for the induction of ectopic bone formation14. On the
other hand, BMP-2 has been also demonstrated to be
a potent regulator of chondrocyte metabolism and differen-
tiation15e17. BMP-2 is found to be upregulated in osteo-
arthritic chondrocytes and diseased cartilage18. These
ﬁndings suggest that BMP-2 can act as a stimulus of57
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cytes. BMP-2, in turn, increases the synthesis of chondro-
cyte extracellular molecules, aggrecan and type II collagen.
For the assessment of the osteoarthritic lesions of the
lumbar facet joint, we developed an animal model by injec-
tion of collagenase into the facet joint in the rat. We showed
that facet joints subjected to collagenase developed OA-like
changes19. The purpose of this study was to examine the
short-term therapeutic effect of rhBMP-2 on the osteoar-
thritic facet joint.
Methods
ANIMALS AND INDUCTION OF EXPERIMENTAL OA
This study was approved by the Institutional Animal Care
and Use Committees of the participating institutions. Two-
month-old Sprague Dawley rats, weighing between 250
and 270 g, were used in this study. Animals were main-
tained in accordance with the NIH ‘Guide for the care and
use of laboratory animals’. Collagenase type II (from Clos-
tridium histolyticum, enzyme activity 321 U/mg) was
obtained from Worthington Biochemical Corporation (Lake-
wood, NJ). The enzyme (1 mg) was dissolved in sterile
phosphate-buffered saline (PBS) (320 ml) (pH 7.4) to pro-
vide a concentration of 1 U/ml. All the surgical procedures
were performed under sterile operating conditions with the
rats under intraperitoneal anesthesia (50 mg/kg ketamine
hydrochloride and 5 mg/kg xylazine hydrochloride). A
6 cm midline incision was made on the back and the para-
spinal muscle was dissected to expose bilateral lumbar
facet joints. Five microliters (5 U, 1 U/ml) of collagenase
was injected into the right lumbar facet joints with a 34
gage blunt NanoFil needle (WPI, Inc., FL) at a rate of 2 ml/
min controlled by an infusion pump. The injection level of
the facet joint was chosen randomly from L3/4 to L5/6.
The fascial layers of the muscle and skin were then closed
in routine fashion. After the surgery, the rats were housed in
an animal room with a 12 h light/12 h dark cycle, and had
free access to food and water. No restriction of movement
was enforced during the test period.
The left-side lumbar facet joints were used as normal
control.
EXPERIMENTAL GROUPS AND INTRA-ARTICULAR
INJECTION OF rhBMP-2
The rhBMP-2 was provided by Medtronic Sofamor Danek
USA, Inc. (Memphis, TN). The rhBMP-2 (1.2 mg) was dis-
solved in sterile distilled water (1 ml) and stored at 80C
until use. Then the rhBMP-2 (1.2 mg/ml) was diluted with
sterile PBS (pH 7.4) to provide the indicated concentrations
(2 ng/ml and 20 ng/ml) before intra-articular injection.
Two weeks after collagenase induction surgery, the rats
were randomly divided into four groups and subjected to
the second surgery (n¼ 12 in each group).
Group 1: Untreated control.
Group 2: PBS (pH 7.4) treatment.
Group 3: 10 ng of rhBMP-2 treatment (concentration:
2 ng/ml).
Group 4: 100 ng of rhBMP-2 treatment (concentration:
20 ng/ml).
Surgical procedures including sterile condition, anesthe-
sia methods and surgical procedures to expose the lumbar
facet joint were the same as described above. In theuntreated group, sham operation was performed without
injection of any material. In the saline-treated and rhBMP-
2-treated groups, 5 ml of saline or rhBMP-2 was injected
into the previously collagenase-injected lumbar facet joints,
respectively. The injection was performed with a 34 gage
blunt NanoFil needle and syringe. After surgery, the wound
was irrigated with normal saline and closed in a routine fash-
ion. The animals were euthanized at 3 or 6 weeks after the
second surgery and the lumbar spines were removed upon
sacriﬁce for histological and immunohistochemical study.
The experimental protocol is diagrammed in Fig. 1(A).
HISTOLOGICAL AND HISTOCHEMICAL EXAMINATION
The lumbar spines were ﬁxed with 10% neutral buffered
formalin for 48 h, decalciﬁed and then embedded in paraf-
ﬁn. Five micrometer sections from the facet joints were
obtained for hematoxylineeosin (H&E) and Safranin O
staining. The articular cartilage in the superior articular
Fig. 1. Experimental protocol and representative section of
collagenase-induced OA of the facet joint. (A) Experimental proto-
col. In the right-side facet joint, OA was induced by an intra-articular
injection of 5 U of collagenase type II. After 2 weeks, four groups
were studied according to the different treatments. (B) Photograph
of facet joint stained with Safranin O. The left-side facet joint was
used as normal control. The right-side facet joint showed spontane-
ous healing without treatment at 3 weeks. IAP¼ inferior articular
process of vertebra. SAP¼ superior articular process of vertebra.
IVD¼ intervertebral disc. Bar¼ 1 mm.
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system (score range: 0e25, from normal to most severe
reaction)20e22 (Table I). The synovium was evaluated ac-
cording to Yoshimi’s histological grading (score range:
0e18, from normal to most severe reaction)21. Two inde-
pendent examiners assessed histological ﬁndings obtained
from these specimens in a blind manner.
IMMUNOHISTOCHEMICAL EXAMINATION
Sections taken from the 6-week treatment groups were
subjected to immunohistochemical examination. Parafﬁn-
embedded sections were deparafﬁnized with xylene and re-
hydrated with ethanol. These sections were incubated in
0.01 M citrate buffer (pH 6) for 8 min at 121C. Endogenous
peroxidase activity was blocked by incubation in 3% H2O2
for 30 min. These sections were washed with Tris-Tween
buffered saline (TTBS) two times. Non-speciﬁc binding was
blocked with normal goat serum [Vectastain rabbit IgG ABC
kit (Vector Laboratories, Inc., Burlingame, CA)] for 30 min at
room temperature. Sections were incubated overnight with
primary antibodies [rabbit polyclonal antibody against rat
type II collagen (Calbiochem, Germany)], diluted 1:100 in
PBST buffer [phosphate buffered saline (pH 7.4), 0.3%
Triton-X-100], at 4C in a humidiﬁed chamber. After washing
three times each for 3 min in TTBS, sections were incubated
with the biotinylated secondary antibody (Vectastain rabbit
Table I
Grading of articular cartilage lesion for histological evaluation
Parameter Grade
(1) Structure
a. Normal 0
b. Surface irregularities 1
c. 1e3 superﬁcial clefts 2
d. >3 superﬁcial clefts 3
e. 1e3 clefts extending into the middle zone 4
f. >3 clefts extending into the middle zone 5
g. 1e3 clefts extending into the deep zone 6
h. >3 clefts extending into the deep zone 7
i. Clefts extending to calciﬁed cartilage 8
j. Complete disorganization or joint space obliteration 9
(2) Chondrocytes
a. Normal 0
b. Slight hypercellularity 1
c. Moderate hypercellularity 2
d. Severe hypercellularity 3
e. Slight cloning (&4) 4
f. Moderate cloning (>4 but &8) 5
g. Severe cloning (>8) 6
h. Slight hypocellularity 7
i. Moderate hypocellularity 8
j. Severe hypocellularity 9
k. Disappearance of cells 10
(3) Safranin O staining
a. Normal 0
b. Loss of staining in the superﬁcial zone for <50%
of the length of the articular surface
1
c. Loss of staining in the superﬁcial zone for S50%
of the length of the articular surface
2
d. Loss of staining in the superﬁcial and middle zones
for <50% of the length of the articular surface
3
e. Loss of staining in the superﬁcial and middle zones
for S50% of the length of the articular surface
4
f. Loss of staining in all three zones for <50% of the
length of the articular surface
5
g. Loss of staining in all three zones for S50% of the
length of the articular surface
6IgGABCkit) for 80 min at room temperature followedby three
3 min washes with TTBS. The horseradish peroxidase
labeled avidinebiotin complexes (Vectastain rabbit IgG
ABC kit) was applied for 30 min followed by two rinses in
TTBS. The peroxidase was detected using 3,30-Diaminoben-
zidine [Vector SK-4100 (Vector Laboratories, Burlingame,
CA)], mixed with distilled water, buffer and H2O2 solution.
Sections were then washed with tap water, dehydrated,
cleared with xylene and mounted. For positive and negative
control, normal rat facet joints were used. Negative control
sections did not receive the primary antibody. Immunostain-
ing for collagen type II was evaluated by using a semi-quan-
titative score. Scoring of the intensity of the staining was
performed according to an arbitrary scale by two observers
in a blinded manner as follows: 0, undetectable staining; 1,
low staining; 2, moderate staining; and 3, strong staining.
DATA AND STATISTICAL ANALYSIS
All data are presented as mean standard deviation. The
KruskaleWallis and ManneWhitney U tests were used to
evaluate the statistical signiﬁcance of differences between
groups. The data were analyzed using SPSS (release
10.0 SPSS Inc., Chicago, IL). P values less than 0.05
were considered signiﬁcant.
Results
DESCRIPTION OF THE MODEL
An axial section of the facet joint from L3/4 stained with
Safranin O is shown in Fig. 1(B). The left-side facet joint
was the normal control (no collagenase injection). The
right-side facet joint showed collagenase-induced OA with-
out treatment. Intra-articular injection of collagenase caused
OA-like changes in the facet joint. These ﬁndings included
the articular matrix lesions (surface irregularity, ﬁssures,
and erosion of articular surface with loss of Safranin O
staining), changes in chondrocytes (cluster or diminishment
of chondrocytes), inﬂammatory reaction of the synovium,
and changes in subchondral bone and bone marrow.
HISTOLOGY OF ARTICULAR CARTILAGE IN THE UNTREATED
OR SALINE-TREATED GROUP
Compared with the normal control [Fig. 2(A and B)], the
histological changes observed in the cartilage of the colla-
genase-exposed joints, untreated or treated with saline,
included deep ﬁssures into the middle and deep zones,
chondrocyte hypercellularity and cloning, and loss of Safra-
nin O staining at 3 weeks [Fig. 2(C and E)]. At 6 weeks, the
degeneration of cartilage was greater. Erosion or denuda-
tion of the cartilage surface with loss of Safranin O staining
and hypocellularity of chondrocyte was observed [Fig. 2(D
and F)].
HISTOLOGY OF ARTICULAR CARTILAGE IN THE
rhBMP-2-TREATED GROUP
In both rhBMP-2-treated groups, a reduction in the sever-
ity of the cartilage lesion was observed after 3 weeks
[Fig. 2(GeJ)]. These ﬁndings include enhanced chondro-
cyte proliferation, decrease in the severity of structure dam-
age, and attenuation of the loss of Safranin O staining.
In the rhBMP-2 100 ng treated group, adverse side effects
were observed in two of the six rats after 3 weeks of treat-
ment. Cartilage overgrowth and severe synovial ﬁbroblast
1360 T.-T. Yeh et al.: Therapeutic effect of rhBMP-2 on lumbar facet joint OAFig. 2. Photographs of facet joint cartilage stained with Safranin O in the normal control group (A,B), collagenase-exposed joint (CeJ), the
untreated group (C,D), the saline-treated group (E,F), the rhBMP-2 10 ng treated group (G,H), and the rhBMP-2 100 ng treated group (I,J)
at 3 and 6 weeks after treatment. In the normal control group (A,B), the articular surface was intact (black arrow). The cartilage matrix stained
strongly with Safranin O. In the untreated group (C,D) and the saline-treated group (E,F), ﬁssures extending into the middle and deep zones
(long white arrow) and cartilage erosion (long black arrow) were observed. The cartilage matrix with loss of Safranin O staining was noted.
Chondrocyte cloning (short white arrow) and hypocellularity of chondrocyte (short black arrow) were observed. Inter-trabecular ﬁbrous tissue
proliferation including young ﬁbroblasts and new blood vessels, and focal new bone formation were observed (open arrow). In the rhBMP-2-
treated groups (GeJ), the severity of structure damage was decreased (arrow). Chondrocyte proliferation was observed. Most of the cartilage
matrix was stained well with Safranin O. Focal changes in subchondral bone were observed (open arrow). Bar¼ 500 mm.proliferation were induced. Both of these caused obliteration
of the facet joint space [Fig. 3(B)]. It also induced the forma-
tion of a cartilage-like proteoglycan containing tissue at the
dorsal aspect of the inferior articular process of vertebra
[Fig. 3(B)]. These structures are referred to as chondro-
phytes. At 6 weeks, these chondrophytes changed into
bone-like structures (osteophytes) by endochondral ossiﬁca-
tion [Fig. 3(C and D)].THE MODIFIED MANKIN SCORE AND THE SCORES OF
SEPARATE HISTOLOGIC PARAMETERS FOR CARTILAGE
ASSOCIATED WITH COLLAGENASE-INDUCED DEGENERATION
The untreated and saline-treated groups showed signiﬁ-
cantly higher mean values for the modiﬁed Mankin score
(P< 0.01) [Fig. 4(A)] and scores of separate histologic
parameters (structure, chondrocyte, and Safranin O
1361Osteoarthritis and Cartilage Vol. 15, No. 12Fig. 3. Safranin O stained sections showed adverse side effects of high dosage rhBMP-2 treatment. (A) Normal control of facet joint. (B) Three
weeks after rhBMP-2 100 ng injection, overgrowth of cartilage (long white arrow) and severe proliferation of synovial ﬁbroblast (short black
arrow) caused an obliteration of joint space. Chondrophyte formation was observed (long black arrow). Multifocal fragmentation of bony tra-
beculae surrounded by osteoclast and ﬁbrous tissue was noted (open arrow). Bone marrow elements were replaced by loosely arranged spin-
dle cells in a ﬁbrous stroma. Hypertrophy of the superior articular process of vertebra was noted (double black arrows). The representative
photographs in A and B were obtained from the same section. (C) Six weeks after rhBMP-2 100 ng injection, newly formed osteophyte (black arrow)
was observed (AeC: bar¼ 1 mm). (D) A higher magniﬁcation of the rectangular outlines in C demonstrates the process of endochondral
ossiﬁcation. Bar¼ 200 mm.staining) compared with the normal control group at 3 and 6
weeks after treatment (all P< 0.01) [Fig. 4(B)]. There were
no differences in these histologic parameters between the
untreated and saline-treated group at week 3 or 6.
The modiﬁed Mankin scores were signiﬁcantly lower in
both rhBMP-2-treated groups than the untreated or saline-
treated groups at 3 and 6 weeks (P< 0.01 for rhBMP-2
10 ng at 3 and 6 weeks, P< 0.01 for rhBMP-2 100 ng at
week 3, and P< 0.05 for rhBMP-2 100 ng at week 6)
[Fig. 4(A)]. No signiﬁcant differences were detected in the
modiﬁed Mankin score between the rhBMP-2 10 ng and
100 ng treated groups [Fig. 4(A)].
The separate histological parameter scores are shown in
Fig. 4(B). When compared with the untreated or saline-
treated groups, the rhBMP-2 10 ng treated group showed
signiﬁcantly lower mean values in the structure score
(P< 0.01 at weeks 3 and 6), the chondrocyte score
(P< 0.01 at week 3, P< 0.05 at week 6), and the Safranin
O staining score (P< 0.05 vs the untreated group at week
3; P< 0.01 vs the saline-treated group at week 3; P< 0.01
at week 6).When the rhBMP-2 10 ng treated groupwas com-
pared with normal control, only the Safranin O staining score
at 6 weeks showed no statistically signiﬁcant differences.
In the rhBMP-2 100 ng treated group, the structure score
at 3 weeks increased signiﬁcantly compared to the rhBMP-
2 10 ng treated group (P< 0.05) and there were no statisti-
cally signiﬁcant differences compared to the untreated or
saline-treated groups. But the structure score in the
rhBMP-2 100 ng treated group decreased at 6 weeks andno signiﬁcant differences were observed compared to the
rhBMP-2 10 ng treated group. In the other histologic para-
meters, when compared to the untreated or saline-treated
groups, the rhBMP-2 100 ng treated group showed signiﬁ-
cantly lower mean scores in chondrocyte score (P< 0.01
at week 3, P< 0.05 at week 6), and the Safranin O staining
score (P< 0.05 at week 3, P< 0.01 at week 6). There were
no statistically signiﬁcant differences in the Safranin O
staining score at 6 weeks between the rhBMP-2 100 ng
treated group and those in the normal control.
HISTOLOGY AND SCORING OF SYNOVIUM
Compared to the normal control [Fig. 5(A and B)], synovial
tissue in all groups showed hypertrophy and hyperplasia of
the synovial lining cells from 3 weeks after the second sur-
gery [Fig. 5(CeJ)]. Subsynovial tissue showed proliferation
of granulation tissue, vascularization, and the inﬁltration of
inﬂammatory cells compared to the normal control.
The synovium scores are shown in Fig. 5(K). The differ-
ences in the synovium scores at weeks 3 and 6 were statis-
tically signiﬁcant between the normal control and other four
groups (P< 0.01). At week 3, the synovium score in the
100 ng of rhBMP-2-treated group increased signiﬁcantly
compared to the saline-treated group (P< 0.01) or the
10 ng of rhBMP-2-treated group (P< 0.05). However, at
week 6, there were no differences in scores between the
rhBMP-2-treated groups and the saline-treated group.
1362 T.-T. Yeh et al.: Therapeutic effect of rhBMP-2 on lumbar facet joint OAFig. 4. Histological scores for cartilage in facet joint for the normal control, the untreated group, the saline-treated group, the rhBMP-2 10 ng
treated group, and the rhBMP-2 100 ng treated group at 3 and 6 weeks post-treatment. The values presented are the means and standard
deviation for six animals. (A) Shown are values of the modiﬁed Mankin scores with comparisons between groups. (B) Shown are scores for the
histologic parameters (structure, chondrocyte, and Safranin O staining) with comparisons between groups. y P< 0.01, * P< 0.05: signiﬁcantly
greater than the normal control group; # P< 0.01, x P< 0.05: signiﬁcantly less than the untreated group; { P< 0.01, z P< 0.05: signiﬁcantly
less than the saline-treated group; D P< 0.05: signiﬁcantly less than the rhBMP-2 100 ng treated group, by the ManneWhitney U test.
Fig. 5. (AeJ) Histological demonstration of synovium stained with H&E, the normal control group (A,B), collagenase-induced OA (CeJ), the
untreated group (C,D), the saline-treated group (E,F), the rhBMP-2 10 ng treated group (G,H), and the rhBMP-2 100 ng treated group (I,J) at 3
and 6 weeks after treatment. In the normal control (A,B), the synovium consists of a thin layer of synovial cells (black arrow) on top of a loose
connective tissue subintimal layer (white arrow). In the collagenase-exposed joint (CeJ), synovial reaction included hypertrophy or hyperplasia
of synovial lining cells (long black arrow), proliferation of granulation tissue (long white arrow), and inﬁltration of inﬂammatory cells.
Bar¼ 100 mm. (K) Synovium score with comparisons between groups at 3 and 6 weeks. # Signiﬁcantly greater than the normal control group
(P< 0.01); x signiﬁcantly greater than the untreated group (P< 0.01); * signiﬁcantly greater than the saline-treated group (P< 0.01);
{ signiﬁcantly greater than the 10 ng of rhBMP-2-treated group (P< 0.05), by the ManneWhitney U test.
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In the untreated and saline-treated groups, some
changes in subchondral bone region immediately adjacent
to the damaged cartilage were observed at 3 weeks. These
changes included proliferation of loose ﬁbrous tissue and
new small vessels in the inter-trabecular space and focal
new bone formation [Fig. 2(C and E)]. At week 6, the sever-
ity of these changes was increased [Fig. 2(D and F)]. In the
rhBMP-2-treated groups, these changes were present only
in small areas [Fig. 2(GeJ)], but more extensive changes in
bone marrow and subchondral bone were observed in two
rats complicated with joint space obliteration in the
rhBMP-2 100 ng treated group. Multifocal fragmentation of
bony trabeculae surrounded by osteoclast and ﬁbrous tis-
sue was noted. Bone marrow elements were replaced by
loosely arranged spindle cells in a ﬁbrous stroma. Com-
pared to the normal control, hypertrophy of the superior
articular process of vertebra was observed (Fig. 3B).
IMMUNOHISTOCHEMICAL FINDINGS
In normal cartilage, the extracellular matrix strongly stains
for type II collagen. Comparedwith normal control specimens,
untreated specimens or saline-treated specimens showed
a statistically signiﬁcant decrease in stain intensity at 6 weeks(all P< 0.01). However, both rhBMP-2-treated specimens
showed no signiﬁcant differences in stain intensity compared
with normal control specimens at 6 weeks (Fig. 6).
Discussion
In the present study, we demonstrated that BMP-2 re-
duced the severity of OA in the cartilage of lumbar facet
joints and increased the presence of type II collagen, the
major extracellular matrix component of articular cartilage.
These results support the concept that, in OA, the anabolic
agent BMP-2 is involved in the repair of cartilage lesions.
Exogenous BMP-2 has potent anabolic activities on adult
chondrocyte in vitro18 and in vivo23,24, increasing proteogly-
can and type II collagen production25e27 and maintaining
the chondrocyte phenotype28. Some studies have shown
that rhBMP-2 can improve the healing of full-thickness
defects of articular cartilage in a rabbit model29,30. But until
now, no in vivo data concerning the effects of rhBMP-2 on
OA cartilage in facet joints were available.
In the present study, the time point for treatment was cho-
sen to be 2 weeks after collagenase injection. Our previously
established animal model showed that OA in the facet joint
was induced after this time period19. In this study, treatment
with BMP-2 effectively alleviated the OA-like changes in theFig. 6. (A) Representative immunohistochemical stain score for collagen type II. Bar¼ 100 mm. (B) Collagen type II was analyzed based upon
the staining intensity using an arbitrary score. The values presented are the means and standard deviation for six animals. z Signiﬁcantly re-
duced compared to the normal control group; x signiﬁcantly reduced compared to the rhBMP-2 10 ng treated group; * signiﬁcantly reduced
compared to the rhBMP-2 100 ng treated group (all P< 0.01), by the ManneWhitney U test.
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10 ng or 100 ng of BMP-2 treatment can reduce the progres-
sion of OA, but the injection of the high dosage BMP-2
caused adverse side effects (obliteration of joint space) in
some rats at 3 weeks. This led to poorer results in the struc-
ture score compared with the low dosage BMP-2 treatment
at this time. Nevertheless the whole modiﬁed Mankin score
showed no signiﬁcant differences between both BMP-2-
treated groups. That was due to the fact that treatment
with the higher dosage of BMP-2 also caused improvement
in chondrocyte growth and reduction of proteoglycan deple-
tion detected by Safranin O staining. Some authors reported
that intra-articular injection of BMP-2 stimulates proteogly-
can synthesis only in normal knees but not in a model of
destructive arthritis31. The proteoglycan synthesis was de-
tected by 35S-sulfate incorporation method in that study31.
Because loss of Safranin O staining is indicative of cartilage
matrix proteoglycan depletion, proteoglycan synthesis can-
not be demonstrated by this stainingmethod. Further studies
are required to establish with certainty the nature of the
changes in proteoglycan synthesis in the osteoarthritic facet
joints after BMP-2 treatment.
In our study, high dosage BMP-2 injections into the facet
joints not only affected articular cartilage, but also induced
the periosteum to form a proteoglycan-rich cartilaginous
structure (chondrophytes). The structure was located in
the dorsal side of inferior articular process of vertebra.
The newly formed cartilaginous structures lost their proteo-
glycan content and developed into osteophytes at a later
time point. Injections of low dosage BMP-2 had little effect
in this respect. In OA, the process of osteophyte formation
at the joint margins is often considered a defense mecha-
nism to increase joint stability. It seldom contributes to the
symptom32. In this study, the newly formed osteophyte
was located in the extra-articular region. This change did
not affect the articular surface structure. Similar chondro-
genic activity after injections with BMP-2 was reported in
the murine knee joint23,24, but the location appeared to be
restricted to the regions in the growth plate in contact with
the patellofemoral joint.
Some authors reported that an injection of BMP-2 into the
murine knee joint had an effect of inducing ﬁbrosis24. In this
study, high dose of rhBMP-2 induced a severe synovium
reaction (lining cell hypertrophy, hyperplasia and subsyno-
vial granulation tissue formation) 3 weeks after treatment.
But the reaction decreased after 6 weeks. The inﬂamed
synovium caused overproduction of the proinﬂammatory
cytokines (such as interleukin-1 (IL-1) and tumor necrosis
factor-alpha (TNF-alpha)) that may contribute to the pro-
gression of OA33,34. On the other hand, some in vitro stud-
ies showed that BMP-2 induced the expression of mRNA
for Sox-9, type II collagen and aggrecan (chondrocyte-
speciﬁc genes) in bovine synovium-derived mesenchymal
progenitor cells35. Our recent observation showed that an
intra-articular injection of rhBMP-2/rhBMP-7 heterodimer
(more potent than rhBMP-236) into the facet joint caused
chondrometaplasia of the synovium (unpublished observa-
tion). Further studies are required to evaluate the balance
between the chondrogenic effect associated with the syno-
vial mesenchymal cells and the catabolic effect of the proin-
ﬂammatory cytokines related to the synovitis and then the
response to BMP-2 treatment.
In our study, subchondral bone involvement was ob-
served after an intra-articular collagenase injection. These
changes developed in the trabecular bone immediately sit-
uated beneath the region of cartilage damage. The changes
are consistent with the initiation of bone remodeling.Although BMP-2 is used for spinal fusion, our results
showed that an intra-articular administration of low dosage
of BMP-2 did not cause overgrowth of subchondral bone.
Previous studies revealed that the therapeutic potential of
BMP-2 by an intra-articular injection into knee joint was lim-
ited, because of the adverse side effects (osteophyte forma-
tion and ﬁbrosis)23,24,37. The complexity of BMP signaling
demonstrates that ﬁne-tuning of this signaling pathway is
likely to be a challenge in the development of regenerative
therapeutic strategies32. Our results show that low dosage
of BMP-2 administration to the osteoarthritic lumbar facet
joint may be able to block or suppress cartilage lesion
progression and avoid some of the adverse side effects of
excessive or prolonged exposure to BMP-2. Although
BMP-2 is not able to overcome all the aspects of the severe
damage induced by an intra-articular collagenase injection,
it becomes apparent that key parameters reﬂecting carti-
lage metabolism (type II collagen and proteoglycan localiza-
tion, chondrocyte proliferation, preservation of joint space)
have been very signiﬁcantly improved.
In summary, the present study demonstrated that a low
dose of rhBMP-2 reduces the progression of structural
changes of the cartilage in a rat lumbar facet joint model
of OA. However, at a high dose of rhBMP-2 it causes
adverse side effects.
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